A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer

go back to reference Siracusa, M., Grappasonni, I., Petrelli, F.: The pharmaceutical care and the rejected constitutional reform: what might have been and what is. Acta Biomed. 88(3), 352–359 (2017). https://doi.org/10.23750/abm.v88i3.6376 CrossRefPubMedPubMedCentral Siracusa, M., Grappasonni, I., Petrelli, F.: The pharmaceutical care and the rejected constitutional reform: what might have been and what is. Acta Biomed. 88(3), 352–359 (2017). https://​doi.​org/​10.​23750/​abm.​v88i3.​6376 CrossRefPubMedPubMedCentral

go back to reference Signorelli, C., Odone, A., Gozzini, A., Petrelli, F., Tirani, M., Zangrandi, A., Zoni, R., Florindo, N.: The missed constitutional reform and its possible impact on the sustainability of the Italian National Health Service. Acta Biomed. 88(1), 91–94 (2017). https://doi.org/10.23750/abm.v88i1.6408 CrossRefPubMedPubMedCentral Signorelli, C., Odone, A., Gozzini, A., Petrelli, F., Tirani, M., Zangrandi, A., Zoni, R., Florindo, N.: The missed constitutional reform and its possible impact on the sustainability of the Italian National Health Service. Acta Biomed. 88(1), 91–94 (2017). https://​doi.​org/​10.​23750/​abm.​v88i1.​6408 CrossRefPubMedPubMedCentral

go back to reference International Agency for Research on Cancer, World Health Organization. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. Press Release no. 263. https://www.who.int/cancer/PRGlobocanFinal.pdf. Accessed 12 Sept 2018 International Agency for Research on Cancer, World Health Organization. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. Press Release no. 263. https://​www.​who.​int/​cancer/​PRGlobocanFinal.​pdf. Accessed 12 Sept 2018

go back to reference Petrelli, F., Scuri, S., Tanzi, E., Nguyễn, T.T.C., Grappasonni, I.: Lifestyles and discomfort in a sample of young Romanian students. J Prev Med Hyg. 59(3), E230–E235 (2018). https://doi.org/10.15167/2421-4248/jpmh2018.59.3.985 CrossRefPubMedPubMedCentral Petrelli, F., Scuri, S., Tanzi, E., Nguyễn, T.T.C., Grappasonni, I.: Lifestyles and discomfort in a sample of young Romanian students. J Prev Med Hyg. 59(3), E230–E235 (2018). https://​doi.​org/​10.​15167/​2421-4248/​jpmh2018.​59.​3.​985 CrossRefPubMedPubMedCentral

go back to reference Grappasonni, I., Scuri, S., Tanzi, E., Kracmarova, L., Petrelli, F.: The economic crisis and lifestyle changes: a survey on frequency of use of medications and of preventive and specialistic medical care, in the Marche Region (Italy). Acta Biomed. 89(1), 87–92 (2018). https://doi.org/10.23750/abm.v89i1.7068 CrossRefPubMedPubMedCentral Grappasonni, I., Scuri, S., Tanzi, E., Kracmarova, L., Petrelli, F.: The economic crisis and lifestyle changes: a survey on frequency of use of medications and of preventive and specialistic medical care, in the Marche Region (Italy). Acta Biomed. 89(1), 87–92 (2018). https://​doi.​org/​10.​23750/​abm.​v89i1.​7068 CrossRefPubMedPubMedCentral

go back to reference Siracusa, M., Petrelli, F.: Trade of food supplement: food or drug supplement?. Recenti Prog Med. 107(9), 465–471 (2016). https://doi.org/10.1701/2354.25224 CrossRefPubMed Siracusa, M., Petrelli, F.: Trade of food supplement: food or drug supplement?. Recenti Prog Med. 107(9), 465–471 (2016). https://​doi.​org/​10.​1701/​2354.​25224 CrossRefPubMed

go back to reference Grappasonni, I., Marconi, D., Mazzucchi, F., Petrelli, F., Scuri, S., Amenta, F.: Survey on food hygiene knowledge on board ships. Int Marit Health 64(3), 160–167 (2013)PubMed Grappasonni, I., Marconi, D., Mazzucchi, F., Petrelli, F., Scuri, S., Amenta, F.: Survey on food hygiene knowledge on board ships. Int Marit Health 64(3), 160–167 (2013)PubMed

go back to reference Grappasonni, I., Petrelli, F., Klusoňová, H., Kračmarová, L.: Level of understanding of medical terms among italian students. Ceska Slov Farm. Winter 65(6), 216–220 (2016) Grappasonni, I., Petrelli, F., Klusoňová, H., Kračmarová, L.: Level of understanding of medical terms among italian students. Ceska Slov Farm. Winter 65(6), 216–220 (2016)

go back to reference Spacilova, L., Klusonova, H., Petrelli, F., Signorelli, C., Visnovsky, P., Grappasonni, I.: Substance use and knowledge among Italian high school students. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 153(2), 163–168 (2009)CrossRefPubMed Spacilova, L., Klusonova, H., Petrelli, F., Signorelli, C., Visnovsky, P., Grappasonni, I.: Substance use and knowledge among Italian high school students. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 153(2), 163–168 (2009)CrossRefPubMed

go back to reference Kračmarová, L., Klusoňová, H., Petrelli, F., Grappasonni, I.: Tobacco, alcohol and illegal substances: experiences and attitudes among Italian university students. Rev. Assoc. Med. Bras. (1992) 57(5), 523–528 (2011)CrossRef Kračmarová, L., Klusoňová, H., Petrelli, F., Grappasonni, I.: Tobacco, alcohol and illegal substances: experiences and attitudes among Italian university students. Rev. Assoc. Med. Bras. (1992) 57(5), 523–528 (2011)CrossRef

go back to reference Petrelli, F., Grappasonni, I., Peroni, A., Kracmarova, L., Scuri, S.: Survey about the potential effects of economic downturn on alcohol consumption, smoking and quality of life in a sample of Central Italy population. Acta Biomed. 89(1), 93–98 (2018). https://doi.org/10.23750/abm.v89i1.7059 CrossRefPubMedPubMedCentral Petrelli, F., Grappasonni, I., Peroni, A., Kracmarova, L., Scuri, S.: Survey about the potential effects of economic downturn on alcohol consumption, smoking and quality of life in a sample of Central Italy population. Acta Biomed. 89(1), 93–98 (2018). https://​doi.​org/​10.​23750/​abm.​v89i1.​7059 CrossRefPubMedPubMedCentral

go back to reference Grappasonni, I., Petrelli, F., Amenta, F.: Deaths on board ships assisted by the Centro Internazionale Radio Medico in the last 25 years. Travel Med Infect Dis. 10(4), 186–191 (2012). https://doi.org/10.1016/j.tmaid.2012.06.006 CrossRefPubMed Grappasonni, I., Petrelli, F., Amenta, F.: Deaths on board ships assisted by the Centro Internazionale Radio Medico in the last 25 years. Travel Med Infect Dis. 10(4), 186–191 (2012). https://​doi.​org/​10.​1016/​j.​tmaid.​2012.​06.​006 CrossRefPubMed

go back to reference Ferlay, J.S.-F., Lortet-Tieulent, E., Rosso, J., Coebergh, S., Jan-Willem, W., Comber, H., Forman, D., Bray, F.: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6), 1374–1403 (2013)CrossRef Ferlay, J.S.-F., Lortet-Tieulent, E., Rosso, J., Coebergh, S., Jan-Willem, W., Comber, H., Forman, D., Bray, F.: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6), 1374–1403 (2013)CrossRef

go back to reference Ferlay, J., Ervik, I.S.,M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F.: Cancer Incidence and Mortality Worldwide. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (2012). Accessed 15 Dec 2016 Ferlay, J., Ervik, I.S.,M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F.: Cancer Incidence and Mortality Worldwide. http://​globocan.​iarc.​fr/​Pages/​fact_​sheets_​cancer.​aspx (2012). Accessed 15 Dec 2016

go back to reference Siegel, R., Naishadham, D., Jemal, A.: Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11–30 (2013)CrossRefPubMed Siegel, R., Naishadham, D., Jemal, A.: Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11–30 (2013)CrossRefPubMed

go back to reference Navada, S., Lai, P., Schwartz, A., Kalemkerian, G.: Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database. J. Clin. Oncol. 24(18_suppl), 7082–7082 (2006) Navada, S., Lai, P., Schwartz, A., Kalemkerian, G.: Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database. J. Clin. Oncol. 24(18_suppl), 7082–7082 (2006)

go back to reference Sher, T., Dy, G.K., Adjei, A.A.: Small cell lung cancer. In: Mayo Clinic Proceedings 2008, vol. 3, pp. 355–367. Elsevier Sher, T., Dy, G.K., Adjei, A.A.: Small cell lung cancer. In: Mayo Clinic Proceedings 2008, vol. 3, pp. 355–367. Elsevier

go back to reference Surveillance, E., and End Results Program: SEER stat fact sheets: lung and bronchus cancer. http://seer.cancer.gov/statfacts/html/lungb.html (2013). Accessed 15 Oct 2017 Surveillance, E., and End Results Program: SEER stat fact sheets: lung and bronchus cancer. http://​seer.​cancer.​gov/​statfacts/​html/​lungb.​html (2013). Accessed 15 Oct 2017

go back to reference Spiro, S.G., Gould, M.K., Colice, G.L.: Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edn.). Chest 132(3 Suppl), 149 s–160 s (2007). https://doi.org/10.1378/chest.07-1358 CrossRef Spiro, S.G., Gould, M.K., Colice, G.L.: Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edn.). Chest 132(3 Suppl), 149 s–160 s (2007). https://​doi.​org/​10.​1378/​chest.​07-1358 CrossRef

go back to reference Cuccioloni, M., Bonfili, L., Mozzicafreddo, M., Cecarini, V., Scuri, S., Cocchioni, M., Nabissi, M., Santoni, G., Eleuteri, A.M., Angeletti, M.: Mangiferin blocks proliferation and induces apoptosis of breast cancer cells via suppression of the mevalonate pathway and by proteasome inhibition. Food Funct. 7(10), 4299–4309 (2016)CrossRefPubMed Cuccioloni, M., Bonfili, L., Mozzicafreddo, M., Cecarini, V., Scuri, S., Cocchioni, M., Nabissi, M., Santoni, G., Eleuteri, A.M., Angeletti, M.: Mangiferin blocks proliferation and induces apoptosis of breast cancer cells via suppression of the mevalonate pathway and by proteasome inhibition. Food Funct. 7(10), 4299–4309 (2016)CrossRefPubMed

go back to reference Shi, Y., Au, J.S., Thongprasert, S., Srinivasan, S., Tsai, C.M., Khoa, M.T., Heeroma, K., Itoh, Y., Cornelio, G., Yang, P.C.: A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J. Thorac. Oncol. 9(2), 154–162 (2014). https://doi.org/10.1097/jto.0000000000000033 CrossRefPubMedPubMedCentral Shi, Y., Au, J.S., Thongprasert, S., Srinivasan, S., Tsai, C.M., Khoa, M.T., Heeroma, K., Itoh, Y., Cornelio, G., Yang, P.C.: A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J. Thorac. Oncol. 9(2), 154–162 (2014). https://​doi.​org/​10.​1097/​jto.​0000000000000033​ CrossRefPubMedPubMedCentral

go back to reference Marchetti, A., Martella, C., Felicioni, L., Barassi, F., Salvatore, S., Chella, A., Camplese, P.P., Iarussi, T., Mucilli, F., Mezzetti, A., Cuccurullo, F., Sacco, R., Buttitta, F.: EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23(4), 857–865 (2005). https://doi.org/10.1200/jco.2005.08.043 CrossRefPubMed Marchetti, A., Martella, C., Felicioni, L., Barassi, F., Salvatore, S., Chella, A., Camplese, P.P., Iarussi, T., Mucilli, F., Mezzetti, A., Cuccurullo, F., Sacco, R., Buttitta, F.: EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23(4), 857–865 (2005). https://​doi.​org/​10.​1200/​jco.​2005.​08.​043 CrossRefPubMed

go back to reference Doval, D., Prabhash, K., Patil, S., Chaturvedi, H., Goswami, C., Vaid, A., Desai, S., Dutt, S., Veldore, V., Jambhekar, N., Mehta, A., Hazarika, D., Azam, S., Gawande, S., Gupta, S.: Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. Oncotargets Ther. 8, 117–123 (2015). https://doi.org/10.2147/ott.s74820 CrossRef Doval, D., Prabhash, K., Patil, S., Chaturvedi, H., Goswami, C., Vaid, A., Desai, S., Dutt, S., Veldore, V., Jambhekar, N., Mehta, A., Hazarika, D., Azam, S., Gawande, S., Gupta, S.: Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. Oncotargets Ther. 8, 117–123 (2015). https://​doi.​org/​10.​2147/​ott.​s74820 CrossRef

go back to reference Sharma, S.V., Bell, D.W., Settleman, J., Haber, D.A.: Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7(3), 169–181 (2007). https://doi.org/10.1038/nrc2088 CrossRefPubMed Sharma, S.V., Bell, D.W., Settleman, J., Haber, D.A.: Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7(3), 169–181 (2007). https://​doi.​org/​10.​1038/​nrc2088 CrossRefPubMed

go back to reference Cioffi, P., Marotta, V., Fanizza, C., Giglioni, A., Natoli, C., Petrelli, F., Grappasonni, I.: Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study. J. Oncol. Pharm. Pract. 19(3), 246–253 (2013). https://doi.org/10.1177/1078155212465994 CrossRefPubMed Cioffi, P., Marotta, V., Fanizza, C., Giglioni, A., Natoli, C., Petrelli, F., Grappasonni, I.: Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study. J. Oncol. Pharm. Pract. 19(3), 246–253 (2013). https://​doi.​org/​10.​1177/​1078155212465994​ CrossRefPubMed

go back to reference De Grève, J., Van Meerbeeck, J., Vansteenkiste, J.F., Decoster, L., Meert, A.P., Vuylsteke, P., Focan, C., Canon, J.L., Humblet, Y., Berchem, G., Colinet, B., Galdermans, D., Bosquée, L., Vermeij, J., Dewaele, A., Geers, C., Schallier, D., Teugels, E.: Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating egfr mutation: a multicenter academic phase II study in caucasian patients (FIELT). PLoS One (2016). https://doi.org/10.1371/journal.pone.0147599 CrossRefPubMedPubMedCentral De Grève, J., Van Meerbeeck, J., Vansteenkiste, J.F., Decoster, L., Meert, A.P., Vuylsteke, P., Focan, C., Canon, J.L., Humblet, Y., Berchem, G., Colinet, B., Galdermans, D., Bosquée, L., Vermeij, J., Dewaele, A., Geers, C., Schallier, D., Teugels, E.: Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating egfr mutation: a multicenter academic phase II study in caucasian patients (FIELT). PLoS One (2016). https://​doi.​org/​10.​1371/​journal.​pone.​0147599 CrossRefPubMedPubMedCentral

go back to reference Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L., You, C.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12(8), 735–742 (2011). https://doi.org/10.1016/s1470-2045(11)70184-x CrossRefPubMed Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L., You, C.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12(8), 735–742 (2011). https://​doi.​org/​10.​1016/​s1470-2045(11)70184-x CrossRefPubMed

go back to reference Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J.M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M.A., Terrasa, J., Munoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J.L., Sanchez, J.J., Molina, M.A., Taron, M., Paz-Ares, L.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239–246 (2012). https://doi.org/10.1016/s1470-2045(11)70393-x CrossRefPubMed Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J.M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M.A., Terrasa, J., Munoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J.L., Sanchez, J.J., Molina, M.A., Taron, M., Paz-Ares, L.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239–246 (2012). https://​doi.​org/​10.​1016/​s1470-2045(11)70393-x CrossRefPubMed

go back to reference Cioffi, P., Laudadio, L., Nuzzo, A., Belfiglio, M., Petrelli, F., Grappasonni, I.: Gemcitabine-induced posterior reversible encephalopathy syndrome: a case report. J. Oncol. Pharm. Pract. 18(2), 299–302 (2012). https://doi.org/10.1177/1078155211424628 CrossRefPubMed Cioffi, P., Laudadio, L., Nuzzo, A., Belfiglio, M., Petrelli, F., Grappasonni, I.: Gemcitabine-induced posterior reversible encephalopathy syndrome: a case report. J. Oncol. Pharm. Pract. 18(2), 299–302 (2012). https://​doi.​org/​10.​1177/​1078155211424628​ CrossRefPubMed

go back to reference World Bank: World development indicators: consumer price index. http://databank.worldbank.org/data/reports.aspx?source=2&series=FP.CPI.TOTL&country=(2015). Accessed 17 July 2015 World Bank: World development indicators: consumer price index. http://​databank.​worldbank.​org/​data/​reports.​aspx?​source=​2&​series=​FP.​CPI.​TOTL&​country=​(2015). Accessed 17 July 2015

go back to reference Ofman, J.J., Sullivan, S.D., Neumann, P.J., Chiou, C.F., Henning, J.M., Wade, S.W., Hay, J.W.: Examining the value and quality of health economic analyses: implications of utilizing the QHES. J. Manag. Care Pharm. JMCP. 9(1), 53–61 (2003). https://doi.org/10.18553/jmcp.2003.9.1.53 CrossRefPubMed Ofman, J.J., Sullivan, S.D., Neumann, P.J., Chiou, C.F., Henning, J.M., Wade, S.W., Hay, J.W.: Examining the value and quality of health economic analyses: implications of utilizing the QHES. J. Manag. Care Pharm. JMCP. 9(1), 53–61 (2003). https://​doi.​org/​10.​18553/​jmcp.​2003.​9.​1.​53 CrossRefPubMed

go back to reference Vergnenegre, A., Massuti, B., de Marinis, F., Carcereny, E., Felip, E., Do, P., Sanchez, J.M., Paz-Arez, L., Chouaid, C., Rosell, R.: Economic analysis of first-line treatment with erlotinib in an EGFR-mutated population with advanced NSCLC. J. Thorac. Oncol. 11(6), 801–807 (2016)CrossRefPubMed Vergnenegre, A., Massuti, B., de Marinis, F., Carcereny, E., Felip, E., Do, P., Sanchez, J.M., Paz-Arez, L., Chouaid, C., Rosell, R.: Economic analysis of first-line treatment with erlotinib in an EGFR-mutated population with advanced NSCLC. J. Thorac. Oncol. 11(6), 801–807 (2016)CrossRefPubMed

go back to reference Khan, I., Morris, S., Hackshaw, A., Lee, S.-M.: Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy. BMJ Open 5(7), e006733 (2015)CrossRefPubMedPubMedCentral Khan, I., Morris, S., Hackshaw, A., Lee, S.-M.: Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy. BMJ Open 5(7), e006733 (2015)CrossRefPubMedPubMedCentral

go back to reference Schremser, K., Rogowski, W.H., Adler-Reichel, S., Tufman, A.L., Huber, R.M., Stollenwerk, B.: Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on EGFR mutation testing in advanced lung adenocarcinoma patients in Germany. Pharmacoeconomics 33(11), 1215–1228 (2015)CrossRefPubMed Schremser, K., Rogowski, W.H., Adler-Reichel, S., Tufman, A.L., Huber, R.M., Stollenwerk, B.: Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on EGFR mutation testing in advanced lung adenocarcinoma patients in Germany. Pharmacoeconomics 33(11), 1215–1228 (2015)CrossRefPubMed

go back to reference Chouaid, C., Crequit, P., Borget, I., Vergnenegre, A.: Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review. Clinicoecon. Outcomes Res. CEOR. 7, 9–15 (2015). https://doi.org/10.2147/ceor.s43328 CrossRef Chouaid, C., Crequit, P., Borget, I., Vergnenegre, A.: Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review. Clinicoecon. Outcomes Res. CEOR. 7, 9–15 (2015). https://​doi.​org/​10.​2147/​ceor.​s43328 CrossRef

go back to reference Chouaid, C., Le Caer, H., Corre, R., Crequit, J., Locher, C., Falchero, L., Dujon, C., Berard, H., Monnet, I., Vergnenegre, A.: Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505). Clin. Lung Cancer 14(2), 103–107 (2013)CrossRefPubMed Chouaid, C., Le Caer, H., Corre, R., Crequit, J., Locher, C., Falchero, L., Dujon, C., Berard, H., Monnet, I., Vergnenegre, A.: Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505). Clin. Lung Cancer 14(2), 103–107 (2013)CrossRefPubMed

go back to reference Vergnenègre, A., Ray, J.A., Chouaid, C., Grossi, F., Bischoff, H.G., Heigener, D.F., Walzer, S.: Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. Clinicoecon. Outcomes Res. CEOR 4, 31 (2012)CrossRef Vergnenègre, A., Ray, J.A., Chouaid, C., Grossi, F., Bischoff, H.G., Heigener, D.F., Walzer, S.: Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. Clinicoecon. Outcomes Res. CEOR 4, 31 (2012)CrossRef

go back to reference Walleser, S., Ray, J., Bischoff, H., Vergnenègre, A., Rosery, H., Chouaid, C., Heigener, D., de Castro Carpeño, J., Tiseo, M., Walzer, S.: Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe. Clinicoecon. Outcomes Res. CEOR 4, 269 (2012) Walleser, S., Ray, J., Bischoff, H., Vergnenègre, A., Rosery, H., Chouaid, C., Heigener, D., de Castro Carpeño, J., Tiseo, M., Walzer, S.: Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe. Clinicoecon. Outcomes Res. CEOR 4, 269 (2012)

go back to reference Lee, V.W., Schwander, B., Lee, V.H.: Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong. Hong Kong Med. J. 20(3), 178–186 (2014)CrossRefPubMed Lee, V.W., Schwander, B., Lee, V.H.: Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong. Hong Kong Med. J. 20(3), 178–186 (2014)CrossRefPubMed

go back to reference Wang, S., Peng, L., Li, J., Zeng, X., Ouyang, L., Tan, C., Lu, Q.: A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. PLoS One 8(3), e55917 (2013)CrossRefPubMedPubMedCentral Wang, S., Peng, L., Li, J., Zeng, X., Ouyang, L., Tan, C., Lu, Q.: A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. PLoS One 8(3), e55917 (2013)CrossRefPubMedPubMedCentral

go back to reference Lv, F., Yu, K., Gao, W., Yu, S.: Cost-utility of erlotinib combined with bevacizumab versus bevacizumab alone after completion of chemotherapy with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J. Chin. Pharm. Sci. 26(6), 447–454 (2017) Lv, F., Yu, K., Gao, W., Yu, S.: Cost-utility of erlotinib combined with bevacizumab versus bevacizumab alone after completion of chemotherapy with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J. Chin. Pharm. Sci. 26(6), 447–454 (2017)

go back to reference Ting, J., Ho, P.T., Xiang, P., Sugay, A., Abdel-Sattar, M., Wilson, L.: Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive non-small-cell lung cancer in the United States. Value Health 18(6), 774–782 (2015)CrossRefPubMed Ting, J., Ho, P.T., Xiang, P., Sugay, A., Abdel-Sattar, M., Wilson, L.: Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive non-small-cell lung cancer in the United States. Value Health 18(6), 774–782 (2015)CrossRefPubMed

go back to reference Christos, C., Chrystelle, L., Cecile, D., Pascal, T., Bernard, A.J., Isabelle, M., Alain, V.: Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504). BMC Cancer 12(1), 301 (2012)CrossRefPubMedCentral Christos, C., Chrystelle, L., Cecile, D., Pascal, T., Bernard, A.J., Isabelle, M., Alain, V.: Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504). BMC Cancer 12(1), 301 (2012)CrossRefPubMedCentral

go back to reference Marshall, D.A., Donald, F., Lacny, S., Reid, K., Bryant-Lukosius, D., Carter, N., Charbonneau-Smith, R., Harbman, P., Kaasalainen, S., Kilpatrick, K.: Assessing the quality of economic evaluations of clinical nurse specialists and nurse practitioners: a systematic review of cost-effectiveness. NursingPlus Open 1, 11–17 (2015)CrossRef Marshall, D.A., Donald, F., Lacny, S., Reid, K., Bryant-Lukosius, D., Carter, N., Charbonneau-Smith, R., Harbman, P., Kaasalainen, S., Kilpatrick, K.: Assessing the quality of economic evaluations of clinical nurse specialists and nurse practitioners: a systematic review of cost-effectiveness. NursingPlus Open 1, 11–17 (2015)CrossRef

go back to reference Jäkel, A., Plested, M., Dharamshi, K., Modha, R., Bridge, S., Johns, A.: A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer. Appl. Health Econ. Health Policy 11(1), 27–43 (2013)CrossRefPubMed Jäkel, A., Plested, M., Dharamshi, K., Modha, R., Bridge, S., Johns, A.: A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer. Appl. Health Econ. Health Policy 11(1), 27–43 (2013)CrossRefPubMed

go back to reference Lange, A., Prenzler, A., Frank, M., Golpon, H., Welte, T., von der Schulenburg, J.-M.: A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). BMC Pulm. Med. 14(1), 192 (2014)CrossRefPubMedPubMedCentral Lange, A., Prenzler, A., Frank, M., Golpon, H., Welte, T., von der Schulenburg, J.-M.: A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). BMC Pulm. Med. 14(1), 192 (2014)CrossRefPubMedPubMedCentral

go back to reference Lyseng-Williamson, K.A.: Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics. 28(1), 75–92 (2010). https://doi.org/10.2165/10482880-000000000-00000 CrossRefPubMed Lyseng-Williamson, K.A.: Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics. 28(1), 75–92 (2010). https://​doi.​org/​10.​2165/​10482880-000000000-00000 CrossRefPubMed

go back to reference Bongers, M.L., Coupe, V.M., Jansma, E.P., Smit, E.F., Uyl-de Groot, C.A.: Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. Pharmacoeconomics. 30(1), 17–34 (2012). https://doi.org/10.2165/11595000-000000000-00000 CrossRefPubMed Bongers, M.L., Coupe, V.M., Jansma, E.P., Smit, E.F., Uyl-de Groot, C.A.: Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. Pharmacoeconomics. 30(1), 17–34 (2012). https://​doi.​org/​10.​2165/​11595000-000000000-00000 CrossRefPubMed

go back to reference Siebert, U.: When Should Decision-Analytic Modeling be Used in the Economic Evaluation of Health Care? Springer, Berlin (2003)CrossRef Siebert, U.: When Should Decision-Analytic Modeling be Used in the Economic Evaluation of Health Care? Springer, Berlin (2003)CrossRef

go back to reference Luijn, J.C.v., Loenen, A.C.v., Gribnau, F.W., Leufkens, H.G.: Choice of comparator in active control trials of new drugs. Ann. Pharmacother. 42(11), 1605–1615 (2008). https://doi.org/10.1345/aph.1L115 CrossRefPubMed Luijn, J.C.v., Loenen, A.C.v., Gribnau, F.W., Leufkens, H.G.: Choice of comparator in active control trials of new drugs. Ann. Pharmacother. 42(11), 1605–1615 (2008). https://​doi.​org/​10.​1345/​aph.​1L115 CrossRefPubMed

go back to reference National Institute for Health and Clinical Excellence: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy. https://www.nice.org.uk/guidance/ta374/chapter/1-Guidance (2015). Accessed 20 Nov 2018 National Institute for Health and Clinical Excellence: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy. https://​www.​nice.​org.​uk/​guidance/​ta374/​chapter/​1-Guidance (2015). Accessed 20 Nov 2018

go back to reference Littlewood, C., Ashton, J., Chance-Larsen, K., May, S., Sturrock, B.: The quality of reporting might not reflect the quality of the study: implications for undertaking and appraising a systematic review. J. Man. Manip. Ther. 20(3), 130–134 (2012). https://doi.org/10.1179/2042618611y.0000000013 CrossRefPubMedPubMedCentral Littlewood, C., Ashton, J., Chance-Larsen, K., May, S., Sturrock, B.: The quality of reporting might not reflect the quality of the study: implications for undertaking and appraising a systematic review. J. Man. Manip. Ther. 20(3), 130–134 (2012). https://​doi.​org/​10.​1179/​2042618611y.​0000000013 CrossRefPubMedPubMedCentral

go back to reference Desai, P.R., Chandwani, H.S., Rascati, K.L.: Assessing the quality of pharmacoeconomic studies in India. Pharmacoeconomics 30(9), 749–762 (2012)CrossRefPubMed Desai, P.R., Chandwani, H.S., Rascati, K.L.: Assessing the quality of pharmacoeconomic studies in India. Pharmacoeconomics 30(9), 749–762 (2012)CrossRefPubMed